Search

Displaying results 1561 - 1570 of 8468 in total
  1. Drug

    Isoeugenol

    go.drugbank.com/drugs/DB14188
    Approved

    It is also a significant dermatologic sensitizer and allergen, and as a result has been restricted to 200 p.p.m. since 1998 according to guidelines issued by the fragrance industry [A34278]. … Isoeugenol is a commonly used fragrance added to many commercially available products, and occurs naturally in the essential oils of plants such as ylang-ylang.

  2. Drug

    Calcium chloride

    go.drugbank.com/drugs/DB01164
    ApprovedInvestigational

    It has several common applications such as brine for refrigeration plants, ice and dust control on roads, and in cement. … It is a salt that is solid at room temperature, and it behaves as a typical ionic halide.

    Mixtures: PAZ. SAN. VE TİC. LTD.
  3. Drug

    Butyrfentanyl

    go.drugbank.com/drugs/DB09173
    ExperimentalIllicit

    [L7811] Butyrfentanyl was first synthesized in 1961 by Janssen Pharmaceuticals as a new opioid analgesic. … [L7811] Butyrfentanyl has no current legitimate clinical applications, but anecdotal reports indicate it may occasionally be surfacing on the grey-market as a recreational drug.

  4. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    many as 40% of patients will experience relapsed or refractory disease. … It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.

  5. Drug

    2-deoxyglucose

    go.drugbank.com/drugs/DB08831
    Investigational

    As an experimental drug, 2-deoxyglucose was demonstrated to work as an anticonvulsant in temporal lobe epilepsy. … 2-deoxyglucose is predominantly used as a diagnostic agent in its radiolabelled form (fluorine-18 is used as the radiolabel).

  6. Drug

    Turoctocog alfa pegol

    go.drugbank.com/drugs/DB14738
    ApprovedInvestigational

    As such, turoctocog alfa pegol is a valuable expansion to the drug therapies available for treating hemophilia A as it ultimately provides a less burdensome and more convenient dosing regimen for patients … It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104].

  7. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    [A3197] Ganaxolone belongs to a class of compounds referred to as neurosteroids. … [L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636]

  8. Drug

    Polatuzumab vedotin

    go.drugbank.com/drugs/DB12240
    ApprovedInvestigational

    humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB … [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141]

  9. Drug

    Cisatracurium

    go.drugbank.com/drugs/DB00565
    ApprovedInvestigational

    This action is antagonized by acetylcholinesterase inhibitors such as neostigmine. … [A243416,A253592] Cisatracurium is an R-cis-R-cis isomer of [atracurium] and has approximately 3 times its neuromuscular blocking potency.

  10. Drug

    Scopolamine

    go.drugbank.com/drugs/DB00747
    ApprovedInvestigational

    [A228758, L31578] Due to its dose-dependent adverse effects, scopolamine was the first drug to be offered commercially as a transdermal delivery system, Scopoderm TTS®, in 1981. … [A228773, L31578] Scopolamine was first approved by the FDA on December 31, 1979, and is currently available as both oral tablets and a transdermal delivery system.[L31578]